Education
About Us
Working with TipRanks
Follow Us
Mainz Biomed B.V. (MYNZ)
NASDAQ:MYNZ
MYNZ Stock Chart & Stats
$1.16
-$0.30(-6.42%)
At close: 4:00 PM EST
$1.16
-$0.30(-6.42%)
Day’s Range― - ―
52-Week Range$0.92 - $8.57
Previous CloseN/A
Volume20.13K
Average Volume (3M)350.23K
Market Cap
$7.52M
Enterprise Value$5.62M
Total Cash (Recent Filing)$6.24M
Total Debt (Recent Filing)$3.27M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Apr 14, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.65
Shares Outstanding5,412,853
10 Day Avg. Volume923,862
30 Day Avg. Volume350,228
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.69
Price to Sales (P/S)4.68
P/FCF Ratio-0.24
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue6.28
Enterprise Value/Gross Profit9.77
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$14.00Price Target Upside1106.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial StrategyMainz Biomed's decentralized commercial strategy includes partnering with lab groups to reduce marketing and infrastructure expenses, and gain access to large physician networks.
Market OpportunityExisting tests with a similar format, such as Cologuard, have achieved commercial success with over $2B in annual sales, presenting an opportunity for Mainz Biomed to capture share.
Product PerformanceMainz Biomed's Next Generation Test leverages mRNA biomarkers to expand the ability to detect pre-cancerous advanced adenomas, enabling prevention of CRC.
Bears Say
Feasibility StudyThe feasibility study seeks to evaluate the panel and machine learning algorithm to determine sensitivity, specificity, and consistency, which presents potential uncertainty.
Unmet NeedPancreatic cancer detection is an area of significant unmet need, with 67k cases in the US each year, the majority of which are caught at Stage 4.
Mainz Biomed B.V. News
MYNZ FAQ
What was Mainz Biomed B.V.’s price range in the past 12 months?
Mainz Biomed B.V. lowest stock price was $0.92 and its highest was $8.57 in the past 12 months.
What is Mainz Biomed B.V.’s market cap?
Mainz Biomed B.V.’s market cap is $7.52M.
When is Mainz Biomed B.V.’s upcoming earnings report date?
Mainz Biomed B.V.’s upcoming earnings report date is Apr 14, 2026 which is in 131 days.
How were Mainz Biomed B.V.’s earnings last quarter?
Mainz Biomed B.V. released its earnings results on Sep 03, 2025. The company reported -$2.65 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.65.
Is Mainz Biomed B.V. overvalued?
According to Wall Street analysts Mainz Biomed B.V.’s price is currently Undervalued.
Does Mainz Biomed B.V. pay dividends?
Mainz Biomed B.V. does not currently pay dividends.
What is Mainz Biomed B.V.’s EPS estimate?
Mainz Biomed B.V.’s EPS estimate is -1.01.
How many shares outstanding does Mainz Biomed B.V. have?
Mainz Biomed B.V. has 5,412,853 shares outstanding.
What happened to Mainz Biomed B.V.’s price movement after its last earnings report?
Mainz Biomed B.V. reported an EPS of -$2.65 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.775%.
Which hedge fund is a major shareholder of Mainz Biomed B.V.?
Currently, no hedge funds are holding shares in MYNZ
Company Description
Mainz Biomed B.V.
Mainz Biomed B.V. (MYNZ) is a biotechnology company focused on the development of innovative products for the early detection of cancer, with a particular emphasis on gastrointestinal diseases. The company operates in the healthcare sector, leveraging advanced molecular diagnostics to create solutions that enhance patient outcomes. Its core product offerings include non-invasive tests that utilize proprietary technology to detect biomarkers associated with various forms of cancer, aiming to provide accurate and timely diagnostics to healthcare providers and patients alike.
MYNZ Stock 12 Month Forecast
Average Price Target
$14.00
▲(1106.90% Upside)
Technical Analysis
Check-Cap
―
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
iSpecimen
―
BioNexus Gene Lab Corp
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
8.54% Other Institutional Investors
91.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---